Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch
1. JNJ's shares are near all-time highs amid strong earnings expectations. 2. Analysts predict Q3 revenue at $23.74 billion, up from last year. 3. JNJ beat revenue estimates in nine of ten recent quarters. 4. Separating consumer health may enhance focus on higher-margin pharma business. 5. Potential M&A with Protagonist Therapeutics could strengthen JNJ's immunology segment.